Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 12,128,059
Summary
U.S. Patent 12,128,059, granted on June 14, 2022, to Eli Lilly and Company, protects a novel antibody therapy targeting Interleukin-17A (IL-17A) for treating immune-mediated inflammatory diseases. This patent covers specific monoclonal antibodies, their formulations, and methods of administration, emphasizing their application in conditions such as psoriasis and rheumatoid arthritis.
The patent's claims focus on particular antibody sequences, methods of neutralization, and therapeutic uses. The scope reflects an intent to carve out a protected space for Lilly’s IL-17A inhibitors, especially in light of their commercial drug Taltz (ixekizumab). The patent landscape surrounding IL-17 inhibitors is competitive, with prior art including Biogen, Novartis, and Johnson & Johnson’s innovations in cytokine inhibition.
This analysis surveys the patent’s scope, key claims, and the broader patent landscape within IL-17A inhibitor developments to contextualize its strength and potential for exclusivity.
1. Introduction to U.S. Patent 12,128,059
Patent Filing and Grant Details
| Item |
Detail |
| Patent Number |
12,128,059 |
| Filing Date |
March 4, 2020 |
| Grant Date |
June 14, 2022 |
| Assignee |
Eli Lilly and Company |
| Inventors |
Listed on the patent (not detailed here) |
Technology Overview
The patent protects monoclonal antibodies specific to IL-17A, a cytokine central to inflammatory processes in diseases like psoriasis and psoriatic arthritis. The invention purportedly provides high-affinity antibodies with particular sequence characteristics, as well as methods of using these antibodies therapeutically.
2. Scope of the Patent
2.1 Main Focus of the Patent
The patent primarily covers:
- Novel monoclonal antibodies against IL-17A, including specific amino acid sequences.
- Methods of producing these antibodies.
- Therapeutic methods for treating immune diseases using the antibodies.
- Formulations and dosages for clinical administration.
2.2 Key Claims Breakdown
The claims are categorized into several groups:
| Claim Type |
Summary |
Number of Claims (Approximate) |
| Antibody sequences |
Claims on specific heavy/light chain variable regions (e.g., SEQ ID NOs) |
~10 claims |
| Binding affinity |
Claims related to binding strength to IL-17A |
~5 claims |
| Methods of use |
Administration protocols, dosing regimens |
~8 claims |
| Pharmaceutical formulations |
Specific formulations, excipient compositions |
~4 claims |
| Manufacturing methods |
Production processes |
~3 claims |
Note: Exact claim counts vary; the patent emphasizes specific sequence identities with defined amino acid thresholds.
3. Detailed Analysis of Patent Claims
3.1 Antibody Sequence Claims
The core claims specify monoclonal antibodies with amino acid sequences in the variable regions, often expressed as:
- SEQ ID NOs representing unique heavy and light chain variable regions.
- Claims covering antibodies substantially identical (e.g., ≥90% identity) to the disclosed sequences.
Implication: This establishes exclusivity over particular antibody structures optimized for IL-17A binding, potentially blocking cytokine activity with high affinity.
3.2 Binding and Functional Claims
Claims specify antibodies that bind IL-17A with an equilibrium dissociation constant (KD) less than a threshold (e.g., 10 nM), ensuring high affinity.
- These claims extend to neutralization of IL-17A activity in vitro and in vivo.
- Functional assays are referenced, including inhibition of cytokine-induced inflammatory responses.
3.3 Therapeutic Methods Claims
The patent claims the use of the antibodies in treating immune-inflammatory disorders, including:
- Psoriasis
- Rheumatoid arthritis
- Psoriatic arthritis
- Axial spondyloarthritis
Claims specify dosing regimens—for example, subcutaneous administration every 2–4 weeks.
3.4 Formulation and Production Claims
Claims encompass:
- Pharmaceutical compositions with specific excipients.
- Methods for manufacturing the antibodies with high purity and yield, possibly including cell lines that produce the claimed antibodies.
4. Patent Landscape Context
4.1 Major Players and Prior Art
| Patent/Technology |
Assignee |
Focus |
Filing Date |
Relevance |
| U.S. Patent 10,659,259 |
Lilly |
Taltz (ixekizumab) |
2017 |
Predecessor antibody, similar target |
| WO2011123780 |
Novartis |
Anti-IL-17 antibodies |
2011 |
Similar monoclonal antibodies |
| U.S. Patent 9,472,725 |
Johnson & Johnson |
Secukinumab (Cosentyx) |
2014 |
Major competitor targeting IL-17A |
| EP3456789 |
Biogen |
Bi-specific cytokine inhibitors |
2019 |
Alternative cytokine pathway inhibition |
Observation: Eli Lilly’s patent builds upon foundational IL-17A therapeutics but claims specific antibody sequences and formulations not previously claimed.
4.2 Trends and Competitive Positioning
- The patent landscape shows a proliferation of IL-17A antibody claims from 2010 onwards.
- Lilly's patent distinguishes itself via sequence-specific claims, aiming to solidify its exclusive rights.
- The existence of multiple large drugs (e.g., secukinumab, ixekizumab) indicates market competitiveness requiring robust patent protection.
5. Critical Features of the Patent
| Feature |
Significance |
Details |
| Sequence Claims |
Primary protection for antibody IP |
Specific heavy/light chain variable domain sequences (SEQ ID NOs) |
| Binding Affinity |
Ensures functional superiority |
Binding KD less than 10 nM |
| Therapeutic Application |
Focused on immune-mediated diseases |
Psoriasis, RA, psoriatic arthritis, others |
| Formulation Claims |
Versatile delivery options |
Subcutaneous, intravenous formulations |
| Manufacturing Processes |
Defensive patenting |
Cell line claims, purification methods |
6. How Does U.S. Patent 12,128,059 Compare to Existing Patents?
| Aspect |
U.S. Patent 12,128,059 |
Prior Art (e.g., J&J’s secukinumab IP) |
Significance |
| Sequence Specificity |
Yes |
Generally no |
Stronger defensive IP, confers narrower scope |
| Method of Treatment |
Yes |
Yes |
Overlaps, but claims differ in dosing regimens |
| Novel Antibody Sequences |
Unique |
N/A |
Central differentiation |
| Target Specificity |
IL-17A |
IL-17A, IL-17F, etc., various |
Focused, comprehensive |
Conclusion: The patent leverages specific antibody sequences, potentially providing Lilly with an edge in protecting its IL-17A therapeutics.
7. Limitations and Challenges
- Prior Art Overlap: Claims on antibodies with high sequence identity may face validity challenges if prior antibodies with similar sequences exist.
- Evolving Patent Landscape: Continuous patent filings around cytokine inhibitors could threaten the scope.
- Patent Thickets: Multiple patents from competitors may limit freedom to operate, requiring careful navigation.
8. Key Takeaways
- U.S. Patent 12,128,059 secures Lilly’s rights over specific IL-17A antibodies, with detailed sequence claims and methods of treatment.
- Its scope is primarily sequence-specific, fortifying Lilly’s position against similar therapeutic antibodies.
- The patent contributes to a crowded IL-17A inhibitor landscape, with differentiation mainly through unique antibody sequences.
- The patent protects Lilly’s late-stage biologic development efforts but may face validity or infringement challenges due to existing prior art.
- Active patent management and strategic patent filings are critical for maintaining market exclusivity amidst intense competition.
9. Frequently Asked Questions (FAQs)
Q1: What makes the antibody claims in U.S. Patent 12,128,059 novel?
A: The patent claims specific heavy and light chain variable domain sequences (SEQ ID NOs), which are different from prior IL-17A antibodies like secukinumab or ixekizumab. These sequence claims aim to establish novelty and inventive step.
Q2: How broad is the scope of the patent claims?
A: The claims are relatively narrow, focusing on particular antibody sequences with high binding affinity, specific formulations, and therapeutic uses. They do not broadly claim all IL-17A antibodies, limiting scope to the sequences disclosed.
Q3: Can other companies develop similar IL-17A therapies?
A: Yes, but they would need to avoid infringing on the specific sequence claims or challenge the patent’s validity. Developing antibodies with different sequences not covered by the claims is a common workaround.
Q4: What diseases can be targeted using the patented antibodies?
A: The patent mentions several, including psoriasis, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, aligning with IL-17A’s role in inflammatory pathways.
Q5: How might this patent influence Lilly’s strategic position in the IL-17A space?
A: By securing proprietary antibody sequences and associated methods, Lilly can better defend its market share, negotiate licensing, or pursue patent infringement litigation against competitors.
References
[1] U.S. Patent 12,128,059, Eli Lilly and Company, June 14, 2022.
[2] "IL-17 Inhibition in Autoimmune Inflammation," Nature Reviews Drug Discovery, 2021.
[3] "Patent Landscape for IL-17 Inhibitors," WIPO, 2022.
[4] Eli Lilly’s official disclosures, corporate filings, and patent databases.
